首页> 外文期刊>Clinical transplantation. >Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center.
【24h】

Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center.

机译:在单个中心进行活体和已故的供体肝移植手术治疗不可切除的肝母细胞瘤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Hepatoblastoma (HB) is the most common malignant liver tumor in children. The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities. We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003. Ten children had a diagnosis of unresectable HB. Mean age at transplantation was 5.8 yr. Eight patients were transplanted with deceased donor grafts. Two patients underwent LDLT. Pre-transplant chemotherapy was used in 90% of cases. Post-transplant survival ranges from 3.7 to 18.6 yr. Three patients died of recurrent disease at 4, 14 and 38 months. The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant. Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.
机译:肝母细胞瘤(HB)是儿童中最常见的恶性肝肿瘤。活体供体肝移植(LDLT)在不可切除的HB治疗中的应用可能会增加新的治疗机会。我们评估了在1985年8月至2003年6月期间接受肝移植治疗无法切除的HB的患者的结局。十名儿童被诊断为不可切除的HB。移植的平均年龄为5.8岁。 8例患者已植入已故的供体移植物。两名患者接受了LDLT。 90%的病例使用了移植前化疗。移植后生存期为3.7至18.6年。 3例患者在4、14和38个月时死于复发性疾病。两名LDLT接受者能够进行移植前化学治疗,并迅速决定是否移植。两者都活着,并且在移植后5.5年和11年时都很好。当等待时间可能不利于患者的生存时,我们的经验支持LDLT和已故的供体肝移植在不可切除的HB管理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号